Human papillomavirus vaccines in plants

References

• IARC Monographs on the Evaluation of Carcinogen Risks to Humans: Human Papillomaviruses. World Health Organization International Agency for Research on Cancer, Lyon, France, 64 (1995).
   Google Scholar
• Bosch FX, Lorincz A, Munoz N, Mejier CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55, 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia M, Jemal A, Ward EM et al.Global Cancer Facts and Figures 2007. American Cancer Society, Atlanta, GA, USA (2007).
   Google Scholar
• Thomas GM. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N. Eng. J. Med.340, 1198–1220 (1999).
   PubMed Web of Science ®Google Scholar
• Reading SA, Dimmock NJ. Neutralization of animal virus infectivity by antibody. Arch. Virol.152, 1047–1059 (2007).
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomavirus infections, a major cause of human cancers. Biochem. Biophys. Acta.1288, F55–F58 (1996).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat. Med.11(4), S5–S10 (2005).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booyt F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA89, 12180–12184 (1992).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine26(Suppl. 10), K1–K16 (2008).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvated bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356(19), 1928–1924 (2007).
   PubMed Web of Science ®Google Scholar
• Haug CJ. Human papillomavirus vaccination – reasons for caution. N. Engl. J. Med.359(8), 861–862 (2008).
   PubMed Web of Science ®Google Scholar
• Michels KB, zur Hausen H. HPV vaccine for all. Lancet374(9686), 268–270 (2009).
   PubMed Web of Science ®Google Scholar
• Schiller JT, Nardelli-Haefliger D. Chapter 17, second generation HPV vaccines to prevent cervical cancer. Vaccine24(Suppl. 3), 147–153 (2006).
   Google Scholar
• Palmer KE, Jenson AB, Kouokam JC, Lasnik AB, Ghim SJ. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer. Exp. Mol. Pathol.86(3), 224–233 (2009).
   Google Scholar
• Hudsun JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of HPV18. J. Virol.64, 519–526 (1999).
   Google Scholar
• Zur Hausen H. Papillomaviruses causing cancer: evasion host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst.92(9), 690–698 (2000).
   PubMed Web of Science ®Google Scholar
• Fehermann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene22(33), 5201–5207 (2003).
   Google Scholar
• Munger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol.78(21), 11451–11460 (2004).
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes40(1), 1–13 (2010).
   PubMed Web of Science ®Google Scholar
• Brinkman JA, Hughes SH, Stone P et al. Therapeutic vaccination for HPV induced cancers. Dis. Markers23, 337–352 (2007).
   PubMed Web of Science ®Google Scholar
• Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol.10, 975–980 (2009).
   Web of Science ®Google Scholar
• Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum. Vaccin.5(10), 671–689 (2009).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.361(19), 1838–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhu T, Ye X et al. Long term protection against HPV E7-positive tumor by a single vaccination of AAV vectors encoting a fusion protein of inactivated E7 of HPV16/18 and heat shock protein 70. Hum. Gene Ther.21(1), 109–119 (2010).
   PubMed Web of Science ®Google Scholar
• Wu TC. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Eur. J. Immunol.37, 310–314 (2007)
   PubMed Web of Science ®Google Scholar
• Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Rev. Anticancer Ther.7(10), 1473–1486 (2007).
   PubMed Web of Science ®Google Scholar
• Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev. Vaccines8(9), 1221–1235 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufman AM, Nieland JD, Jochmus I et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int. J. Cancer121(12), 2794–2800 (2007).
   Google Scholar
• Di Bonito P, Grasso F, Mochi S et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology395(1), 45–55 (2009).
   Google Scholar
• Hung CF, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol. Ther.8(4), 421–439 (2008).
   PubMed Web of Science ®Google Scholar
• Gomez Lim MA. Transgenic plants in therapeutically valuable protein production. Transgenic Plant J.1, 256–266 (2007).
   Google Scholar
• Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discov. Today14(1/2), 16–24 (2009).
   PubMed Web of Science ®Google Scholar
• Yusibov V, Rabindran S. Recent progress in the development of plant-derived vaccines. Expert Rev. Vaccines7(8), 1173–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma AK, Sharma MK. Plants as bioreactors: recent developments and emerging opportunities. Biotechnol. Adv.27(6), 811–832 (2009).
   PubMed Web of Science ®Google Scholar
• Rybicki EP. Third International Conference on Plant-Based Vaccines and Antibodies. Expert Rev. Vaccines8(9), 1151–1155 (2009).
   Google Scholar
• Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotech. J.8(5), 620–637 (2010).
   PubMed Web of Science ®Google Scholar
• Rose RC, Lane C, Wilson S, Suzich JA, Rybicki EP, Williamson A-L. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine17(17), 2129–2135 (1999).
   PubMed Web of Science ®Google Scholar
• Gerber S, Lane C, Brown DM et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol.75(10), 4752–4760 (2001).
   PubMed Web of Science ®Google Scholar
• Thönes N, Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology369(2), 375–388 (2007).
   PubMedGoogle Scholar
• Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol.148(9), 1771–1786 (2003).
   PubMed Web of Science ®Google Scholar
• Warzecha H, Mason HS, Lane C et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J. Virol.77(16), 8702–8711 (2003).
   PubMed Web of Science ®Google Scholar
• Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J. Virol.77(17), 9211–9220 (2003).
   PubMed Web of Science ®Google Scholar
• Liu HL, Li WS, Lei T et al. Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta Biochim. Biophys. Sin (Shanghai).37(3), 153–158 (2005).
   PubMedGoogle Scholar
• Varsani A, Williamson AL, Stewart D, Rybicky EP. Transient expression of human papillomavirus type16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res.120(1–2), 91–96 (2006).
   PubMed Web of Science ®Google Scholar
• Palmer KE, Benko A, Doucette SA et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine24(26), 5516–5525 (2006).
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang YY et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology321(2), 205–216 (2004).
   PubMed Web of Science ®Google Scholar
• Kohl T, Hitzeroth II, Stewart D et al. Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin. Vaccine Immunol.13(8), 845–853 (2006).
   PubMed Web of Science ®Google Scholar
• Kohl TO, Hitzeroth II, Christensen ND, Rybicki EP. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol.7, 56 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol.7, 152–158 (2004).
   PubMed Web of Science ®Google Scholar
• Maclean J, Koekemoer M, Olivier AJ et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol.88(5), 1460–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Regnard GL, Halley-Stott RP, Tanzer FL, Hitzeroth II, Rybicki EP. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol. J.8(1), 38–46 (2010).
   PubMed Web of Science ®Google Scholar
• Lenzi P, Scotti N, Alagna F et al. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplantomic tobacco. Transgenic Res.17(6), 1091–1102 (2008).
   PubMedGoogle Scholar
• Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J.6(5), 427–441 (2008).
   PubMedGoogle Scholar
• Pereira R, Hitzeroth II, Rybicki EP. Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch. Virol.154(2), 187–197 (2009).
   Google Scholar
• Jagu S, Karanam B, Gambhira R et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl Cancer Inst.101(11), 782–792 (2009).
   PubMed Web of Science ®Google Scholar
• Slupetzky K, Gambhira R, Culp TD et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine25(11), 2001–2010 (2007).
   PubMed Web of Science ®Google Scholar
• McCormick AA, Reddy S, Reinl SJ et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a Phase I clinical study. Proc. Natl Acad. Sci. USA105(20), 10131–10136 (2008).
   PubMed Web of Science ®Google Scholar
• Frazer HI. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol.4, 46–54 (2004).
   PubMed Web of Science ®Google Scholar
• Franconi R, Di Bonito P, Dibello F et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumour protection. Cancer Res.62, 3654–3658 (2002).
   PubMed Web of Science ®Google Scholar
• Roggero P, Ciuffo M, Benvenuto E, Franconi R. The expression of a single-chain Fv antibody fragment in different plant hosts and tissues by using potato virus X as a vector. Protein Expr. Purif.22(1), 70–74 (2001).
   PubMed Web of Science ®Google Scholar
• Dalsaard K. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and mouth disease vaccines. Arch. Gesamte Virusforsch.44, 243–254 (1974).
   Google Scholar
• Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type16-transformed cells. Eur. J. Immunol.23, 2242–2249 (1993).
   PubMed Web of Science ®Google Scholar
• Franconi R, Massa S, Illiano E et al. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Int. J. Immunopathol. Pharmacol.19(1), 187–197 (2006).
   Google Scholar
• Di Bonito P, Grasso F, Mangino G et al. Immunomodulatory activity of a plant extract containing human papillomavirus 16-E7 protein in human monocyte-derived dendritic cells. Int. J. Immunopathol. Pharmacol.22(4), 967–978 (2009).
   Google Scholar
• Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology281(2), 231–238 (2001).
   PubMed Web of Science ®Google Scholar
• Musiychuk K, Stephenson N, Bi H et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Resp. Viruses1(1), 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Massa S, Franconi R, Brandi R et al. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine25, 3018–3021 (2007).
   PubMed Web of Science ®Google Scholar
• Venuti A, Massa S, Mett V et al. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine27, 3395–3397 (2009).
   PubMedGoogle Scholar
• Skarjinskaia M, Karl J, Araujo A et al. Production of recombinant proteins in clonal root cultures using episomal expression vectors. Biotechnol. Bioeng.100(4), 814–819 (2008).
   Google Scholar
• Massa S, Skarjinskaia M, Mett V, Venuti A, Yusibov V, Franconi R. Plant platforms for producing anti-cancer therapeutic vaccines. Presented at: Third International Conference on Plant-Based Vaccines and Antibodies. University of Verona, Verona, Italy, 15–17 June 2009.
   Google Scholar
• Torrent M, Llompart B, Lasserre-Ramassamy S et al. Eukaryotic protein production in designed storage organelles. BMC Biol.7, 5 (2009).
   Google Scholar
• Ohlschläger P, Pes M, Osen W et al. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wild type-specific T cell response. Vaccine24(15), 2880–2893 (2006).
   PubMed Web of Science ®Google Scholar
• Savelyeva N, Munday R, Spellenberg MB, Lomonossoff GP, Stevenson FK. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat. Biotech.19, 760–764 (2001).
   PubMed Web of Science ®Google Scholar
• Savelyeva N, Zhu D, Stevenson FK. Engineering DNA vaccines that include plant virus coat proteins. Biotechnol. Genet. Eng. Rev.20, 101–114 (2003).
   Web of Science ®Google Scholar
• Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum. Gene Ther.19(4), 354–364 (2008).
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveley-O’Carroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res.56, 21–26 (1996).
   PubMed Web of Science ®Google Scholar
• Morgenfeld M, Segretin ME, Wirth S. Potato virus X coat protein fusion to human papillomavirus 16 E7 oncoprotein enhance antigen stability and accumulation in tobacco chloroplast. Mol. Biotechnol.43, 243–249 (2009).
   PubMed Web of Science ®Google Scholar
• Stirpe F, Battelli MG. Ribosome-inactivating proteins: progress and problems. Cell Mol. Life Sci.63(16), 1850–1866 (2006).
   PubMedGoogle Scholar
• Cerovská N, Hoffmeisterová H, Pecenková T et al. Transient expression of HPV16 E7 peptide (aa 44–60) and HPV16 L2 peptide (aa 108–120) on chimeric potyvirus-like particles using potato virus X-based vector. Protein Exp. Purif.58(1), 154–161 (2008).
   PubMedGoogle Scholar
• Paz De la Rosa G, Monroy-García A, Mora-García ML et al. An HPV 16 L1-based chimeric human papillomavirus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol. J.6, 1–11 (2009 ).
   Google Scholar